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Introduction
The nucleolus is a subnuclear compartment organized around
the tandem repeats of ribosomal DNAs. It has become evident
that the nucleolus is a very dynamic organelle. All nucleolar
components are engaged in complex movements (Andersen et
al., 2005; Olson and Dundr, 2005). Most, if not all, nucleolar
proteins shuttle between the nucleolus and the nucleoplasm at
a relatively fast pace (Andersen et al., 2005; Chen and Huang,
2001; Dundr et al., 2000; Phair and Misteli, 2000; Tsai and
McKay, 2005). Several nucleoplasmic proteins, such as p53
(Rubbi and Milner, 2000), telomerase reverse transcriptase
(TERT) (Wong et al., 2002), the murine double minute protein
(MDM2) (Weber et al., 1999), and the von Hippel-Lindau
tumor suppressor protein (Mekhail et al., 2004; Mekhail et al.,
2005), have been shown to associate with the nucleolar
structure under physiological or pathological conditions,
suggesting that it serves as a form of subcellular machinery to
activate or inactivate proteins that may not always reside in it.
Compartmentalization provides a fast and energy-conserving
mechanism to modulate protein activities without changing
their expression levels. The movement of nuclear proteins in
and out of the nucleolus allows cells to respond to a variety of
environmental stimuli in a fast and dynamic fashion (Carmo-
Fonseca et al., 2000; Tsai, 2004).
The complexity of the molecular devices controlling the
protein flux through the nucleolus is manifested in many
aspects. Unlike proteins that travel to membrane-bound
organelles, most nucleolar proteins do not share a consensus
targeting sequence, and their nucleolar localization signal
(NoLS) often overlaps with their nuclear localization signals
(NLS) (Martel et al., 2006; Reed et al., 2006; Sheng et al.,
2004; You et al., 2005). Within the nucleolus, distinct
subdomains can be identified by their electron-dense properties
and by the distribution of proteins or ribosomal RNAs (Politz
et al., 2002; Politz et al., 2005). In addition to their nucleolar-
nucleoplasmic shuttling behavior, some nucleolar proteins
might temporally associate with other subnuclear organelles,
such as the Cajal body, paraspeckles, and the promyelocytic
leukemia nuclear body (Bernardi et al., 2004; Fox et al., 2002;
Sleeman et al., 2003). The dynamics of nucleolar proteins can
be further modified by environmental signals, such as the pH
(Mekhail et al., 2004) and the intracellular GTP level (Tsai and
McKay, 2005). It remains unclear why and how these proteins
move so rapidly between different nuclear compartments.
Understanding the mechanisms underlying this process may
provide insight into the regulation of nucleolar functions in
protein synthesis, posttranscriptional modification of RNAs,
cell-cycle progression, and stress response (Pederson, 1998;
Rubbi and Milner, 2003).
The dynamic movement of the nucleolar protein
nucleostemin is controlled by a GTP-driven cycle (Misteli,
2005; Tsai and McKay, 2005). Nucleostemin is highly enriched
in the embryonic, mesenchymal, and neural stem cells, and
several types of human cancers (Baddoo et al., 2003; Liu et al.,
Nucleostemin plays an essential role in maintaining the
continuous proliferation of stem cells and cancer cells. The
movement of nucleostemin between the nucleolus and the
nucleoplasm provides a dynamic way to partition the
nucleostemin protein between these two compartments.
Here, we show that nucleostemin contains two nucleolus-
targeting regions, the basic and the GTP-binding domains,
that exhibit a short and a long nucleolar retention time,
respectively. In a GTP-unbound state, the nucleolus-
targeting activity of nucleostemin is blocked by a
mechanism that traps its intermediate domain in the
nucleoplasm. A nucleostemin-interacting protein, RSL1D1,
was identified that contains a ribosomal L1-domain.
RSL1D1 co-resides with nucleostemin in the same
subnucleolar compartment, unlike the B23 and fibrillarin,
and displays a longer nucleolar residence time than
nucleostemin. It interacts with both the basic and the GTP-
binding domains of nucleostemin through a non-nucleolus-
targeting region. Overexpression of the nucleolus-targeting
domain of RSL1D1 alone disperses nucleolar nucleostemin.
Loss of RSL1D1 expression reduces the compartmental size
and amount of nucleostemin in the nucleolus. Our work
reveals that the partitioning of nucleostemin employs
complex mechanisms involving both nucleolar and
nucleoplasmic components, and provides insight into the
post-translational regulation of its activity.
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5125Nucleolar retention of nucleostemin
2004; Tsai and McKay, 2002). It enters the nucleolus in a GTP-
bound form, mediated in part by its basic (B) domain. When
nucleostemin is in the GTP-unbound state, its nucleolar
targeting ability is suppressed by the intermediate (I)-domain
(Tsai and McKay, 2005). The GTP-binding capability of
nucleostemin regulates its shuttling in and out of the nucleolus
and, given its function in maintaining the proliferation of stem
cells and cancer cells, may be used to transduce extracellular
signals into the mitotic state of these cells in a fast and
reversible manner. In this study, we attempted to dissect the
protein(s) and structural components that regulate the
compartmentalization of nucleostemin. We showed that the
nucleolar localization of nucleostemin is mediated by its B-
domain and GTP-binding (G)-domain, which interact with the
gene ribosomal L1-domain-containing 1 (RSL1D1), belonging
to the L1p/L10e family. RSL1D1 colocalizes with
nucleostemin in the same subnucleolar domain and affects
the nucleolar distribution of nucleostemin in the mutant-
overexpression and small interference RNA (siRNA)-
knockdown paradigms. By contrast, the movement of
nucleostemin to the nucleolus is gated by a GTP-controlled
mechanism that uses the I-domain as a nucleoplasmic anchor.
Together, these mechanisms determine the partitioning of
nucleostemin between the nucleolus and the nucleoplasm. 
Results
Nucleostemin containes two nucleolar localization
regions
Previously, we have shown that deletion of the B-domain in
nucleostemin (NSdB) or the Gly256 to Val (G256V) point
mutation reduces the nucleolar localization of nucleostemin,
and that a combination of both [NSdB(G256V)] completely
excludes it from the nucleolus (Tsai and McKay, 2005). To test
whether the G-domain is sufficient to mediate nucleolar
localization by itself, green fluorescent protein (GFP)-tagged
nucleostemin mutants containing either the B-domain  (B) or
the G-domain, fused to an SV40 NLS (nlsG), or both (NSdA),
were examined for their distribution in U2OS cells (Fig. 1A,B).
Our results showed that the B- and the G-domain proteins were
predominantly localized to the nucleolus (Fig. 1B, see B and
nlsG). Nucleolar signal intensities relative to the nucleoplasmic
intensities (N/P values) appeared stronger in the wild-type NS
and the NSdA mutant that contain both the the B- and the G-
domains than in the B and nlsG mutants that contain only one
of the two domains (NS, 3.0; NSdA, 3.2; B, 2.0; nlsG, 1.9). To
find out whether GTP-binding regulated the nucleolar
localization of the nlsG mutant, we made a mutation on the
conserved Gly256 residue in this mutant [nlsG(256)], and
showed that this double mutant remained in the nucleolus.
However, if the I-domain was included, the G256V mutation
could disrupt the nucleolar distribution of the nlsGI mutant
[nlsGI(256)]. In order to transport mutant proteins without NLS
into the nucleus, a SV40 NLS (PKKKRKV) was engineered at
the N-terminus of the G and GI mutants. This SV40 NLS did
not display any nucleolar localization capability by itself when
fused to a cytoplasmic hydrolase protein, yielding construct
nlsHd3. These data demonstrate that both the B- and the G-
domain possess nucleolus-targeting activities. The nucleolar
localization of the G-domain alone does not require GTP-
binding, but is gated by the I-domain in a GTP-dependent
manner.
Long retention of nucleostemin in the nucleolus is
mediated by its G-domain
Because the nucleolar residence time of the B-domain is much
shorter than that of the full-length nucleostemin (Tsai and
McKay, 2005), the G-domain might mediate the long retention
of nucleostemin in the nucleolus. We confirmed this idea by
the FRAP (fluorescence recovery after photobleaching)
approach, which showed that the nucleolar retention time of
the GI-domain was longer than that of the B-domain or the full-
length nucleostemin (Fig. 1C1). The difference in FRAP
between the GI-domain and the full-length nucleostemin could
be attributed to the deletion of the acidic (A)-domain, because
the GI-domain exhibited the same recovery kinetics as the
NSdA mutant during the first 20 seconds after photobleaching
(Fig. 1C2, 1C3). Thirty seconds after photobleaching, the GI-
domain appeared to recover more fluorescence signals in the
nucleolus than NSdA did. In these experiments, we included
the I-domain because a deletion of this region prolonged the
FRAP recovery time significantly and often caused cell death
(Tsai and McKay, 2005). Because the I-domain has no
nucleolar localization activity, we conclude that the G-domain
is responsible for the long nucleolar retention of nucleostemin.
Nucleoplasmic retainment of nucleostemin is
independent of the B- and G-domain 
The I-domain might block the nucleolar localization of the
GTP-unbound nucleostemin by masking its nucleolus-
targeting regions or by a mechanism independent of the B- and
G-domain, thereby retaining nucleostemin in the nucleoplasm.
To determine which of the two mechanisms was used by
nucleostemin, we first examined whether the I-domain can
interact with the B- or G-domain. Using affinity binding
assays, we showed that a fusion construct of glutathione S-
transferase (GST) and the I-domain was unable to bind any of
the B- or G-domain-containing mutants, regardless of their
GTP-binding states (Fig. S1 in supplementary material). To
determine whether the nucleoplasmic-retaining activity of the
I-domain depended on the B- or G-domain, we tethered
another nucleolar protein B23/nucleophosmin (B23) to an I-
domain fragment at its N-terminus (myc-I-B23, Fig. 2A1) or
C-terminus (B23-I-HA) (Fig. 2B1). Compared with the wild-
type B23, the presence of the I-domain significantly increased
the nucleoplasmic amount of B23 in the fusion mutant. This
was not caused by the fusion per se, because Myc- or HA-
tagged B23 proteins (Fig. 2A2 or 2B2, respectively) and B23
fused N- or C-terminally to GFP (239 residues versus 176
residues in the I-domain) showed wild-type B23 distribution
(Fig. 2A3 versus 2B3, respectively). To further support these
findings, we created I-domain fusion proteins of three
ribosomal proteins, L5, L11 and L23, and showed that the I-
domain can shift these proteins from a predominant nucleolar
distribution to a nucleoplasmic distribution (Fig. 2C,D,E).
These results demonstrate that the I-domain possesses the
activity to retain nucleostemin in the nucleoplasm that is
independent of the B- and G-domain.
Identification of a nucleostemin-interacting protein
RSL1D1
To identify proteins involved in the nucleolar or nucleoplasmic
retention of nucleostemin, a yeast two-hybrid screen was set
up where a GAL4–DNA-binding-domain fusion of the GI-
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domain was used to screen a mouse embryonic day 7 (E7)
cDNA library for potential binding proteins. From a total of
5.6 million clones screened, two positive ones were isolated.
They encoded an in-frame full-length cDNA of the RSL1D1
(GenBank accession number NM_025546.1) (Fig. 3A). The
biochemical interaction between nucleostemin and RSL1D1
was shown by affinity binding assays in which the HA-tagged
nucleostemin or RSL1D1 could be specifically retained by
agarose-bound GST fusions of RSL1D1 (Fig. 3B1) or
nucleostemin (Fig. 3B2), but not by the GST backbone protein.
To confirm the interaction between nucleostemin and RSL1D1
in vivo, HEK293 cells were transfected with both HA-tagged
nucleostemin and Myc-tagged RSL1D1 expression plasmids
for coimmunoprecipitation. Our results showed that
nucleostemin can be co-purified with RSL1D1 by anti-Myc
antibody but not by mouse IgG (Fig. 3C, first row). Similarly,
RSL1D1 was detected in the nucleostemin protein complex
Journal of Cell Science 119 (24)
precipitated by anti-HA antibody (third row). Finally, we
demonstrated that endogenous nucleostemin in HEK293 cells
and Myc-tagged RSL1D1 can be co-purified in the same
protein complexes precipitated by nucleostemin antiserum
(Fig. 3D, left panel) or by anti-Myc antibody (right panel), but
not by the control preimmune serum or mouse IgG. These
results show that nucleostemin and RSL1D1 can form a protein
complex both in vitro and in vivo.
RSL1D1 colocalizes with nucleostemin in the same
subnucleolar compartments, unlike the distribution of
B23 and fibrillarin 
To address whether the interaction between nucleostemin and
RSL1D1 is physiologically relevant, we first characterized
RSL1D1 expression during embryogenesis and in the adult
tissues. Developmental northern blots showed that the RSL1D1
message is abundantly expressed in the E10.5 and E12.5
Fig. 1. Nucleostemin containes two distinct nucleolus-targeting regions with different nucleolar retention time. (A) Diagram of nucleostemin
(NS) protein structure and mutant constructs used to determine the nucleolus-targeting domains of nucleostemin. An SV40 nuclear localization
signal (NLS, black circle) was introduced in mutants that lack an endogenous NLS (black boxes). Numbers indicate the aa positions. B, basic;
C, coiled-coil; G, GTP-binding; I, intermediate; A, acidic. (B) Subcellular distributions of mutant proteins in U2OS cells were revealed by a C-
terminal GFP-tag; counterstaining with anti-B23 antibody is shown in the right upper quadrants in all panels on a 50% scale. Both the B- and
the G-domains (nlsG) displayed a nucleolar distribution pattern. Mutation of the conserved GTP-binding residue G256, yielding nlsG(256), did
not affect the nucleolar localization of the G-domain alone. In the presence of the I-domain, such a mutation [nlsGI(256)] abolished its
nucleolar localization. A cytoplasmic hydrolase protein (Hd3) was tagged with the SV40 NLS to demonstrate that this sequence was not
sufficient to confer nucleolar localization. Bar, 10 m. (C1) FRAP recovery times (x-axis, in seconds) of the B-domain (trace 1), the full-length
nucleostemin (trace 2) and the GI-domain (trace 3) were determined in CHO cells transiently transfected with the GFP-fusion constructs. The
y-axis represents the percentage of fluorescence intensity in the bleached area relative to the prebleached intensity. (C2) The FRAP recovery
time of the GI-domain (nlsGI) and the A-domain deletion mutant (NSdA) was measured as described in the Materials and Methods.
(C3) Statistical analyses at 5, 10, 20 and 30 seconds (mean ± standard error of mean (s.e.m.), n=20).
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5127Nucleolar retention of nucleostemin
embryos and decreased after E12.5. This expression window
overlapped with that of nucleostemin (Fig. 4A). In adult mice,
RSL1D1 was most expressed in the testis, followed by muscle
and eye. Other tissues expressed RSL1D1 at a low level (Fig.
4B). These results show that, the expression pattern of RSL1D1
coincides with that of nucleostemin in the early embryos and
in the adult testis (Tsai and McKay, 2002) and RSL1D1 is more
widely expressed than nucleostemin.
The subcellular distribution of RSL1D1 and nucleostemin
was determined in U2OS cells by high-resolution confocal
analyses. Our results showed that nucleostemin was non-
uniformly distributed within the nucleolus (Fig. 4C1 and 4C2).
To a great extent, the RSL1D1 signal, detected by a Myc
epitope or GFP tag, co-localized with nucleostemin (Fig. 4C3
and supplementary material Fig. S2A). This distribution
pattern was not identical to that of B23, which was less in the
center and more in the periphery of the nucleolus (Fig. 4D
and supplementary material Fig. S2B). Conversely, the
subnucleolar domains where fibrillarin resided showed low
nucleostemin and RSL1D1 signals (Fig. 4E and supplementary
material Fig. S2C). These colocalization data provide a
physiological basis for the nucleostemin-RSL1D1 interaction,
and suggest a connection between the nucleolar localization of
nucleostemin and RSL1D1.
RSL1D1 stays longer in the nucleolus than full-length
nucleostemin
Next, we used FRAP experiments to determine how long
RSL1D1 stayed in the nucleolus. A GFP-fusion of RSL1D1
was expressed in CHO cells. A FRAP paradigm was designed
where a circle of 1 m in diameter within the nucleolus was
bleached (Fig. 5A, arrows), and the fluorescence recovery in
the bleached area was recorded for 31.6 seconds (Fig. 5B). Our
results showed that 5 seconds after photobleaching, the
fluorescence recovery of RSL1D1 reached only 72.8% of the
prebleached level, compared with the 80.9% recovery of
nucleostemin (Fig. 5C). The FRAP recovery rate of RSL1D1
continued to lag behind that of nucleostemin throughout the
31.6-second recording period (P<0.001, n=20).
Nucleostemin-RSL1D1 interaction is mediated by the B-
and G-domains of nucleostemin
To address whether the nucleostemin-RSL1D1 interaction is
related to the nucleolus-targeting activity of nucleostemin, we
Fig. 2. The nucleolar localization of nucleostemin is gated by a nucleoplasmic-retaining mechanism independent of its nucleolus-targeting
domains. (A1-E2) When fused to the N-terminus (A1) or the C-terminus (B1) of B23, the I-domain of nucleostemin significantly increased the
amount of B23 in the nucleoplasm compared with the epitope-tagged (A2, B2) or the GFP-tagged proteins (A3, B3) at their respective ends.
This nucleoplasmic-retaining activity of the I-domain could also be transferred to three ribosomal proteins, L5, L11 and L23. Unlike the
nucleolar distributions of their original proteins (C2, D2, E2), the I-domain fusions of these proteins (C1, D1, E1) localized almost exclusively
in the nucleoplasm. Anti-fibrillarin or anti-B23 immunostainings of the same cells are shown in the bottom panels. Fusion constructs are
depicted at the bottom of each panel. Bars, 10 m.
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investigated which domains of nucleostemin are required for
this interaction using a panel of truncated nucleostemin
mutants (Fig. 6A). Affinity binding assays demonstrated that
deletion of any single B-, C-, G-, I- or A-domain did not affect
the binding of nucleostemin to RSL1D1, indicating that
multiple regions are involved (Fig. 6B). Using complex
deletion mutants, we showed that RSL1D1 interacts with both
the BC- and the GI-domain individually, but very little or
not at all with the G-, IA- or GI(256) mutants (Fig. 6C).
The RSL1D1-binding domain of nucleostemin was further
narrowed down to the B-domain of the BC mutant (Fig. 6D1)
and to the GI1-domain of the GI mutant, consisting of the G-
domain plus the N-terminal 73 residues of the I-domain (Fig.
6D2). Finally, we confirmed that the B- and G-domains are the
major binding interfaces for RSL1D1. A double deletion of
these two domains in nucleostemin (NSdBG) completely
abolished the binding between nucleostemin and RSL1D1,
whereas a double deletion of the C- and I-domains in
nucleostemin (NSdCI) had no effect on the interaction
between nucleostemin and RSL1D1 (Fig. 6D2). These results
demonstrate that the RSL1D1-interacting and nucleolus-
targeting domains of nucleostemin are the same.
Separate domains in RSL1D1 mediate its targeting to
the nucleolus and its binding to nucleostemin
RSL1D1 contains an L1 domain (aa 150-254), a coiled-coil
Journal of Cell Science 119 (24)
domain (aa 270-316) and three predicted NLS (Fig. 7A). To
determine whether the nucleostemin-interacting domain of
RSL1D1 overlaps with its nucleolar localization domain, we
examined the nucleostemin-binding abilities and distribution
patterns of the truncated RSL1D1 mutants (Fig. 7A). Affinity
binding assays showed that GST fusions of the BC- and the
GI-domain specifically retain the C-terminal half of RSL1D1
(aa 255-452), but not the N-terminal half mutant (aa 1-254)
that includes the L1-domain (Fig. 7B). We further narrowed
the nucleostemin-interacting domain of RSL1D1 down to its
last 136 aa without the coiled-coil domain (aa 317-452). The
distribution patterns of Myc-tagged truncated RSL1D1
mutants in relation to nucleostemin were determined by
double-labeled immunofluorescence (Fig. 7C-L). The 150-316
aa region of RSL1D1, which contained the L1-domain, the
coiled-coil domain and one NLS, was localized in the
nucleolus (Fig. 7C). The 1-149 aa region by itself was
distributed in the cytoplasm (Fig. 7D). When fused with an
SV40 NLS, some of it entered the nucleolus (Fig. 7E). The
nucleostemin-interacting 317-452 aa domain was diffusely
localized in the nucleus (Fig. 7F) and, in some cells, displayed
a slightly higher intensity in the nucleus than in the
nucleoplasm (Fig. 7G). Further dissection of the nucleolus-
targeting 150-316 aa region revealed that without an NLS, the
L1 domain (aa 150-254) was trapped mostly in the cytoplasm.
Only a small proportion of it was located around the nucleolus
Fig. 3. Nucleostemin interacts with RSL1D1. (A) Protein sequences of mouse RSL1D1 (GenBank accession no. NM_025546) and two closely
related genes, L10A (GenBank accession no. NM_011287), and L10 (GenBank accession no. XM_138143), were aligned by the Clustal W
(1.81) program. Shaded and underlined areas represent the ribosomal L1 and the coiled-coil domain, respectively. Three putative NLS are
marked in bold. *, fully conserved residues; :, conservation of strong groups; ., conservation of weak groups. Biochemical interaction between
nucleostemin and RSL1D1 was shown by affinity binding assays using a GST-RSL1D1 fusion protein to pull down HA-tagged nucleostemin
(B1) or a GST-nucleostemin fusion protein to pull down HA-tagged RSL1D1 (B2). (C) The nucleostemin-RSL1D1 interaction was confirmed
by coimmunoprecipitation in both directions. HEK293 cells were co-transfected with HA-tagged nucleostemin and Myc-tagged RSL1D1 and
immunoprecipitated with anti-Myc antibody (rows 1 and 2, left column, -myc), anti-HA antibody (rows 3 and 4, rows, left column, -HA), or
mouse IgG (rows 1-4, right column). The co-purified proteins (rows 1 and 3) and the immunoprecipitates (rows 2 and 4) were detected by
immunoblotting with the indicated polyclonal antibodies. (D) Left panel: Myc-tagged RSL1D1 was co-purified with endogenous nucleostemin
in HEK293 cells by nucleostemin antiserum (-NS), but not by preimmune serum (Cntrl). Right panel: endogenous nucleostemin was also be
co-purified with Myc-tagged RSL1D1 by anti-Myc antibody (-myc) but not by mouse IgG.
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5129Nucleolar retention of nucleostemin
(Fig. 7H). When fused to an SV40 NLS, the nlsL1 mutant was
able to enter the nucleolus (Fig. 7I). Notably, the nucleolar
signal of nucleostemin was either diminished or absent in many
cells expressing this nlsL1 mutant (Fig. 7J, bottom panel). The
coiled-coil domain (aa 255-316) exhibited a diffuse nuclear
distribution similar to that of the 317-452 aa region (Fig. 7K).
Finally, except for the nlsL1 construct, neither the mutants nor
the wild-type RSL1D1 (Fig. 7L) appeared to affect the
Fig. 4. Tissue and subcellular distributions of RSL1D1 overlap with those of nucleostemin. (A,B) Northern blot analyses of expression patterns
of RSL1D1 and nucleostemin in the developing whole embryos from E10.5 to E16.5 (A) and in the adult mice (B). (C1-E3) Double-labeled
immunofluorescence and confocal analyses showing colocalization of endogenous nucleostemin (NS, red) and Myc-tagged RSL1D1 (green)
(C), NS (red) and B23 (green) (D), NS (red) and fibrillarin (Fib, green) (E). High magnifications of the indicated areas (squares) are shown in
(C2, D2 and E2). Dashed lines delineate the nucleo-cytoplasmic boundaries. Bars, 5 m for C1, D1, E1; 2 m for C2, D2 and E2.
Quantification of colocalization is shown in C3, D3 and E3. All pixels were plotted on the basis of their red (y-axis) and green (x-axis)
fluorescence intensities, and pseudocolored on the basis of the event frequency, with red representing the highest and blue the lowest event
frequency. 
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Fig. 5. RSL1D1 has a longer nucleolar retention time than nucleostemin. (A) Time-sequenced FRAP images of nucleostemin and RSL1D1 in
the nucleolus. A circle of 1 m in diameter within the nucleolus (arrows) was bleached. Of note, low intensity spots in the upper panels (*)
existed before photobleaching. Numbers indicate the time in seconds after the bleaching event. Bars, 1 m. (B) The FRAP recovery curves of
RSL1D1 and nucleostemin depict the average of the fluorescence recovery level (y-axis; n=20) relative to the prebleached intensity (set as 1)
over a 31.6-second period following photobleaching (x-axis) in seconds. Error bars represent ± standard deviations (±s.d.) and are omitted on
the top and bottom side of the RSL1D1 and nucleostemin recovery curves for clarity. (C) t-test analyses of the FRAP results were conducted at
5, 10, 20 and 30 seconds after photobleaching (mean ± s.e.m.; n=20).
Fig. 6. RSL1D1 interacts with the B- and G-domains of nucleostemin. (A) Schematic diagrams of truncated nucleostemin mutants used to
determine RSL1D1-interacting domain(s). (B) Affinity binding assays showing that GST fusions of RSL1D1 are able to pull down all single-
domain deletion mutants of nucleostemin, suggesting involvement of multiple regions. (C) The use of truncation mutants showed that RSL1D1
binds both the BC- and the GI-domains, but not the G- and IA-domains or a GI-domain containing a G256V mutation (GI(256)).
(D) Nucleostemin RSL1D1-binding domains were further narrowed down to the B-domain of the BC mutant (D1) and the GI1-domain of the
GI mutant (D2). Double-deletion mutants (NSdBG and NSdCI) confirmed the importance of the B- and G-domains, but not of the C- and I-
domains, in mediating the interaction of nucleostemin and RSL1D1 (D2).
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distribution of endogenous nucleostemin (Fig. 7C-L, bottom
panels). These data demonstrate that the nucleostemin-
interacting domain of RSL1D1 contributes little to its nucleolar
localization. Instead, the nucleolar distribution of RSL1D1 is
mediated mostly by the L1-domain and partially by the 1-149
aa region, neither of which binds nucleostemin.
Overexpression of nlsL1 reduces the amount of
nucleostemin in the nucleolus
The nlsL1 mutant was localized in the nucleolus, but lacked
the ability to bind nucleostemin. Compared with non-
transfected cells, overexpression of this mutant distinctively
reduced the amount of nucleostemin in the nucleolus (Fig.
8A1). Despite its reduced intensity, the distribution pattern of
the remaining nucleostemin signal in those cells resembled the
nucleostemin distribution in non-transfected cells (Fig. 8A2).
In some cells, the nucleostemin signals were scattered around
the nlsL1 signals (Fig. 8B), indicating that overexpression of
this mutant could lead to either a disruption of the nucleolar
structure or a displacement of nucleostemin from its original
compartment. To determine whether nlsL1 disrupts nucleolar
organization, we examined its effect on the distributions of
fibrillarin and B23, which are involved in pre-ribosomal RNA
processing and ribosome maturation, respectively. Judging
Fig. 7. Nucleolar distribution and the nucleostemin-interaction of RSL1D1 are controlled by separate domains. (A) RSL1D1 contains an L1
domain (aa 150-254), a coiled-coil domain (C) and three putative NLS (black boxes). Myc-tagged truncated RSL1D1 mutants were generated
to map nucleostemin-interacting and nucleolus-targeting regions. (B) Affinity binding assays show that GST fusions of both the BC- and GI-
domains bind the (aa 317-452) part of RSL1D1 that does not contain the L1- or C-domain. (C-L) Anti-Myc and anti-nucleostemin double-
labeled immunofluorescence demonstrate that the 150-316 aa region of RSL1D1 is localized in the nucleolus (C). The N-terminal 1-149 aa
region is cytoplasmic by itself (D), and becomes partially nucleolar when tagged with an SV40 NLS (E). Distribution of the C-terminal 317-
452 aa region is diffuse in the nucleus (F), with some cells showing more signals in the nucleolus than in the nucleoplasm (G). Within the aa
150-316 segment, the L1 domain (150-254) by itself is primarily cytoplasmic (H), but becomes mostly nucleolar when fused to an SV40 NLS
(I,J, nlsL1). The coiled-coil domain (255-316) is diffusely localized in the nucleus (K). The nucleostemin signal is diminished or absent from
the nucleolus of many cells expressing nlsL1 (J). Bars, 10 m.
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Fig. 8. Overexpression of a nucleolar
form of the L1-domain (nlsL1)
disperses nucleostemin from the
nucleolus. (A1) The intensities of
nucleostemin signals in the nucleolus
are diminished or disappear in many
cells that express the nlsL1 mutant.
(A2) High magnification of the nlsL1-
expressing cell show that its
remaining nucleostemin signals
display a reticular pattern of
distribution, similar to the
nucleostemin distribution in wild-type
cells. (B) In some cells, nucleostemin
is scattered around the nlsL1 signals.
Overexpression of the nlsL1 mutant
does not affect the signal intensities or
the distribution patterns of fibrillarin
(C) or B23 (D). Bars, 10 m for A1;
5 m for A2, B, C, D.
Fig. 9. Loss of RSL1D1 expression decreases the compartmental size and protein amount of nucleostemin and B23 in the nucleolus. (A1) The
knockdown efficiency of the RSL1D1-specific siRNA duplex (siRSL1D1) was examined at the RNA and protein levels. Compared with
samples treated with the control siRNA duplex (siNEG), siRSL1D1 can reduce the endogenous RSL1D1 mRNA by 73% (top panel), and the
exogenously expressed Myc-tagged RSL1D1 protein by 43% in HEK293 cells (bottom panel). The siRSL1D1 treatment does not affect the
total amount of nucleostemin protein (A2). Tub, -tubulin for northern blots (NB), and -tubulin for western blots (WB). The effect of a partial
loss of RSL1D1 expression on the nucleolar distribution of nucleostemin was measured in U2OS cells double-labeled with anti-nucleostemin
(Ab2438) and anti-B23 antibody. Quantitative analyses show that a partial knockdown of RSL1D1 expression decreased the total nucleolar area
(No) occupied by nucleostemin (B1) (P<0.001, n=130). A similar effect was seen in the B23-containing regions (B2). On the y-axis the
percentage of cells at or below the size indicated on the x-axis is shown. On the x-axis the nucleoluar area in units of 100 pixels (equals 0.89
m2) is shown. (C) Immunofluorescence images representative of the average of each group are shown. Dashed lines delineate the nucleo-
cytoplasmic boundaries. Bars, 5 m.
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5133Nucleolar retention of nucleostemin
from the signal intensities and distribution patterns, neither
fibrillarin (Fig. 8C) nor B23 (Fig. 8D) was affected by nlsL1
overexpression. These results show that nlsL1 might function
as a dominant-negative regulator for the nucleolar distribution
of nucleostemin.
Partial loss of RSL1D1 expression decreases the
nucleolar distribution of nucleostemin
Because the RSL1D1-interacting domains of nucleostemin
coincide with nucleolar localization regions, but the
nucleostemin-interacting domain and the nucleolus-targeting
domain of RSL1D1 are distinctively separated, we reason that
the nucleolar distribution of nucleostemin might be secondary
to that of RSL1D1. To test this idea, we knocked down the
expression of RSL1D1 using the small interfering RNA
(siRNA) approach and examined the distribution of
nucleostemin. Compared with the control siRNA (siNEG)
knockdown samples, treatment with RSL1D1-specific siRNA
(siRSL1D1) reduced the RSL1D1 expression by 73% at the
RNA level and 43% at the protein level, but did not affect the
total protein level of nucleostemin (Fig. 9A). siRSL1D1-
treated cells showed a mild but significant decrease in the
nucleolar size defined by the nucleostemin signal (Fig. 9B1,
9C, and Table 1). The nucleostemin-positive nucleolar area
(No) and the ratio of this area to the total nuclear area (No/Nu)
in siRSL1D1-treated cells were 35.0±1.2 (per 100 pixels) and
14.1±0.4%, compared with siNEG-treated cells at 42.4±1.3
(per 100 pixels) and 16.8±0.4% (P<0.001, n=130). Although
siRSL1D1 treatment produced a statistically insignificant
(P=0.09) increase in the nucleolar fluorescence intensity of
nucleostemin relative to its nucleoplasmic fluorescence
intensity (N/P), the overall immunofluorescence of
nucleostemin in the nucleolus relative to its nucleoplasmic
fluorescence intensity (NoxN/P) was still decreased by the
RSL1D1 knockdown (P=0.05). No difference was seen in the
total nuclear area and the number of nucleolus per cells
between the siRSL1D1-treated and siNEG-treated samples,
indicating that these nucleolar phenotypes were not caused by
sampling errors or by changes in the overall cell condition
(Table 1). To determine whether siRSL1D1 knockdown
interferes with other nucleolar proteins, we immunolabeled
B23 in the same sets of cells stained with anti-nucleostemin
antibody. Our analyses showed that siRSL1D1 also reduced the
nucleolar occupancy of B23, measured by the size of the
nucleolus, the ratio of the nucleolar and nuclear size, and the
total fluorescence in the nucleolus (Fig. 9B2, 9C, and Table 1).
Together, these results show that a partial loss of RSL1D1
expression reduces the amount of nucleostemin and B23 in the
nucleolus.
Discussion
This study is designed to understand the mechanism that
regulates the distribution of nucleostemin between the
nucleolus and the nucleoplasm. Our data reveal a complex
model that involves nucleolar and nucleoplasmic components,
as well as distinct domains of nucleostemin (Fig. 10). The
nucleolar localization of nucleostemin is mediated by its B-
and G-domains, and blocked by its I-domain. This I-domain-
mediated nucleoplasmic-retaining mechanism does not depend
on the B- or the G-domain, but is disabled by the GTP-bound
G-domain. Without the I-domain, the G-domain is localized
in the nucleolus regardless of its GTP-binding state.
Nucleostemin interacts with an L1-domain-containing
gene, RSL1D1, identified by a yeast two-hybrid screen.
Nucleostemin and RSL1D1 colocalize in the same
subnucleolar compartment. The interaction between these two
proteins requires the B- and G-domains of nucleostemin on one
hand and a non-nucleolar, non-L1-domain-containing region of
RSL1D1 (aa 317-452) on the other hand. Overexpression of a
nucleolar RSL1D1 mutant lacking the nucleostemin-binding
ability (nlsL1) disperses the nucleostemin signal from the
nucleolus. A partial loss of RSL1D1 expression reduces mostly
the compartmental size but also the protein amount of
nucleostemin in the nucleolus.
The B-domain and the G-domain of nucleostemin display
two distinctively different nucleolar retention properties. It is
unclear why two domains with different retention kinetics are
needed for the nucleolar localization of nucleostemin. One
possibility is that the short retention signal (the B-domain) is
used to fine-tune the long retention signal (the G-domain).
When both domains are present (NSdA), its FRAP signal
becomes less than that of the GI-domain only during the very
late phase of the recovery (Fig. 1C3). Another possibility is
that the B-domain and the G-domain take part in different
biological activities coordinated by nucleostemin. At the
molecular level, we were unable to distinguish the B- and the
G-domain by their interacting partners. Both domains bind the
same nucleolar protein, RSL1D1. Notably, the interaction
between the G-domain and RSL1D1 also requires the N-
terminal 73 aa of the I-domain, which contains the G2 and G3
Table 1. siRNA knockdown of RSL1D1 (siRSL1D1), its effect on nucleolar distributions of nucleostemin and B23, nuclear
size and number of nucleoli per cell
Nucleostemin B23 Nuclear area Nucleoli
No (per 100 pixels*) No/Nu (%) N/P NoxN/P No (per 100 pixels*) No/Nu(%) N/P NoxN/P (per 100 pixels*) per cell
siRSL1D1 35.0±1.2 14.1±0.4 3.4±0.1 118.8±5.4 40.2±1.3 16.3±0.4 3.5±0.1 136.5±5.2 247.1±5.6 4.3±0.1
siNEG 42.4±1.3 16.8±0.4 3.2±0.1 131.6±4.5 46.3±1.4 18.4±0.4 3.3±0.1 152.9±5.9 251.4±5.1 4.5±0.1
P-value <0.001 <0.001 0.09 0.05 <0.001 <0.001 0.14 0.02 0.54 0.14
No, nucleolar area.
No/Nu, nucleolar-to-nuclear area. 
N/P, ratio of nucleolar-to-nucleoplasmic fluorescence intensity. 
NoxN/P, overall immunofluorescence of the nucleolus relative to its nucleoplasmic fluorescence intensity.
siNEG, control siRNA targeting a scrambled sequence.
*, 100 pixels equal 0.89 m2.
P-values were calculated by t-test.
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GTP-binding motifs that are less conserved and shorter than
the G4 and G1 motifs. To molecularly dissect the different
domains of nucleostemin and RSL1D1, some truncated
mutants are inevitably left without an NLS. Since nuclear
translocation is a prerequisite step for initiating nucleolar
localization after the protein is synthesized, we used an SV40
NLS to bring those mutant proteins into the nucleus. Although
we have shown that this SV40 NLS alone is not sufficient to
confer nucleolar distribution (Fig. 1B, nlsHd3), it may still
cooperate with and enhance the activity of the NoLS of
nucleostemin to a different degree when compared to the NLS
of nucleostemin. This might explain why the G-domain can
enter the nucleolus when tagged with an SV40 NLS, but is
unable to bind RSL1D1 by itself.
RSL1D1 represents a nucleolar component that regulates the
nucleolar localization of nucleostemin. At the molecular level,
the nucleolus-targeting and RSL1D1-interacting activities of
Journal of Cell Science 119 (24)
nucleostemin are encoded by the same domains, whereas the
nucleolus-targeting and nucleostemin-binding domains of
RSL1D1 are different. At the functional level, the nucleolar
retention time of RSL1D1 is longer than that of the full-length
nucleostemin and resembles the FRAP recovery kinetics of the
GI-domain. Overexpression of an RSL1D1 mutant, nlsL1, can
disperse the nucleostemin signal from the nucleolus. Since the
nucleolar nlsL1 cannot bind nucleostemin, this mutant may
occupy the nucleolar binding sites for endogenous RSL1D1,
and functions as a dominant-negative regulator for the
nucleolar nucleostemin. A partial loss of RSL1D1 expression
reduces the nucleostemin-defined nucleolar size by 18%.
Although the nucleostemin signal intensity in the nucleolus
appeared elevated, the overall nucleostemin fluorescence signal
in the nucleolus of siRSL1D1-treated cells was still reduced by
10% compared with the siNEG-treated cells (P=0.05). The
changes in the nucleostemin distribution associated with the
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Fig. 10. Diagram of the mechanism controlling nucleostemin distribution between the nucleolar and nucleoplasmic compartments, and the
effects of RSL1D1 knockdown and nlsL1 overexpression. Nucleostemin in the GTP-unbound state is blocked from entering the nucleolus by a
nucleoplasmic-retaining mechanism that acts on the I-domain. GTP binding releases this lock and allows nucleostemin to move into the
nucleolus. Nucleostemin interacts with nucleolar protein RSL1D1 through the nucleolus-targeting B- and G-domains. When not bound by GTP,
the GI-domain fails to interact with RSL1D1, suggesting a link between the nucleolar exit of nucleostemin and GTP hydrolysis. RSL1D1 co-
resides with nucleostemin in subnucleolar domains surrounding fibrillarin. A partial knockdown of RSL1D1 expression reduces the
compartmental size and, to a lesser extent, the protein amount of nucleostemin in the nucleolus, supporting the idea that RSL1D1 provides the
nucleolar binding site for nucleostemin. Overexpression of nlsL1 disperses nucleostemin signals from the nucleolus by occupying the nucleolar
binding sites for the endogenous RSL1D1 capable of interacting with nucleostemin. NoLS, nucleolar localization sequence(s); NOR, nucleolar
organization region; Fib, fibrillarin.
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5135Nucleolar retention of nucleostemin
siRSL1D1 treatment are mild, which might be owing to an
incomplete knockdown effect. It is difficult to assess the
efficiency of siRSL1D1 treatment at the endogenous protein
level without an anti-RSL1D1 antibody. Notably, the
siRSL1D1 treatment also reduces the nucleolar distribution of
B23, suggesting that RSL1D1 directly regulates the nucleolar
distribution of B23, or affects B23 indirectly through
nucleostemin. This finding also indicates that the nucleolus is
composed of different compartments that are interconnected
with one another. Together, these results support the in vivo
importance of RSL1D1 in regulating the nucleolar localization
of nucleostemin.
Given the role of RSL1D1 in the nucleolar distribution of
nucleostemin and that RSL1D1 cannot bind the GTP-unbound
GI mutant [Fig. 6C; GI(256)], the timing of the dissociation
between nucleostemin and RSL1D1, as well as the nucleolar
exit of nucleostemin, might be triggered by the GTP hydrolysis
of nucleostemin. GTP hydrolysis is a tightly regulated
biological event for all GTP-binding proteins. Nucleostemin
belongs to a subfamily of GTPases containing a MMR_HSR1
domain in the Pfam database. Unlike the Ras protein, all
members in this subfamily have four GTP-binding motifs
arranged in a circularly permuted order, where the G4 motif is
localized N-terminally to the G1, G2 and G3 motifs (Daigle et
al., 2002; Leipe et al., 2002). To date, only one gene in this
family in multicellular organisms has been experimentally
shown to contain some intrinsic GTPase activities (Reynaud et
al., 2005). To address if the nucleolar exit of nucleostemin is
triggered by GTP hydrolysis, we generated a Pro258Val
mutation in nucleostemin that corresponded to the position of
the mutation in the constitutively active GTPase activity in the
human RAS mutant [RAS(G12V)]. However, our NS(P258V)
mutant failed to yield a constitutively active phenotype
regarding its GTP-binding or nucleolar retention property,
indicating that some fundamental differences in the GTP-
binding structures exist between the MMR_HSR1 family and
the small GTPase family.
The modular property of nucleostemin provides a molecular
basis for predicting the roles of proteins that interact with
different parts of nucleostemin. For example, a protein that
binds the B- and/or G-domains might mediate the nucleolar
targeting/retention step of nucleostemin or might be
transported to the nucleolus by nucleostemin, or might act
downstream of the nucleolar functions of nucleostemin.
Supporting this idea, we have shown that the B- and G-
domain-interacting RSL1D1 is involved in the nucleolar
localization of nucleostemin. Human RSL1D1 was previously
identified as one of the genes that are inhibited by cellular
senescence (GenBank accession numbers AAN41298 and
AY154473), or overexpressed in the non-small-cell lung
cancer (GenBank accession number AAT06742) or in human
trophoblast cells (CAA07491). Similarly, nucleostemin is
highly expressed by several types of human cancer cells (Liu
et al., 2004; Tsai and McKay, 2002), and its expression is
suppressed in mouse embryonic fibroblast cells undergoing
cellular senescence (Zhu et al., 2006). RSL1D1 displays a
wider distribution than nucleostemin during embryogenesis
and in adult mice. The fact that some tissues express RSL1D1
but not nucleostemin suggests that it may also work as a
nucleolar hub for proteins other than nucleostemin. Proteins
interacting with the I-domain remain unidentified at this
moment. They are expected to serve as the nucleoplasmic
docking sites for nucleostemin. The nucleoplasmic-retaining
activity of the I-domain does not depend on the B- or G-
domains, suggesting that it can be used by other nucleolar
proteins. A BLAST search of the GenBank database identifies
only two protein sequences that share significant homologies
with the I-domain of nucleostemin. They belong to the
guanine nucleotide binding protein-like 3 (nucleolar)-like
(Gnl3l) and Ngp1 (Gnl2) genes, which represent the closest
family members for nucleostemin in vertebrates. It will be
interesting to see whether those nucleoplasmic docking sites,
once identified, are free-floating or tethered to the nuclear
matrix and whether all nucleostemin family genes share the
same docking molecule.
In conclusion, we show that the dynamic distribution of
nucleostemin between the nucleolus and the nucleoplasm is
controlled by a combination of nucleolar and nucleoplasmic
mechanisms. This work raises the idea that partitioning of
nucleolar proteins between subnuclear compartments employs
complex molecular devices to achieve a specific, rapid and
reversible response.
Materials and Methods
Recombinant plasmids and site-directed mutagenesis
Deletions and point mutations were introduced by the stitching PCR method as
described previously (Tsai and McKay, 2002; Tsai and McKay, 2005). The final
PCR products were subcloned into pCIS expression vectors and confirmed by
sequencing. Full-length RSL1D1 cDNAs were cloned from mouse embryonic stem
cells and human MCF7 cells by reverse-transcription PCR.
Cell culture, transfection and immunostaining
Three different cell lines, which all expressed nucleostemin, were used in this study.
HEK293 cells were used for biochemical studies because of their high transfection
efficiency and protein production. U2OS cells were used for subcellular distribution
analysis because of their large and flat-shaped nuclei. CHO cells were used for the
FRAP experiments because of their simple nucleolar morphology. Cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
5% fetal bovine serum (FBS; Hyclone), penicillin (50 IU/ml), streptomycin
(50ug/ml), and glutamine (1%). Plasmid transfections were performed using a
standard calcium phosphate method for HEK293 cells or Lipofectamine-Plus
reagents (Invitrogen) for U2OS cells, and analyzed 2 days after transfection.
Immunofluorescence studies were performed as described previously (Tsai and
McKay, 2005). Cells were fixed with fresh 4% paraformaldehyde on ice for 15
minutes. Primary antibodies included: affinity-purified polyclonal Ab2438 (1:500;
chicken IgY) for endogenous nucleostemin, monoclonal anti-HA antibody (1:2000;
HA.11, Covance), monoclonal anti-myc antibody (1:1000; 9E10, Covance),
monoclonal anti-fibrillarin antibody (1:1000; 38F3, EnCor), and monoclonal anti-
B23 antibody (1:1000, Zymed). Secondary antibodies were conjugated with Red-X
or FITC.
Yeast two-hybrid screen
A sequence containing the GTP-binding and the intermediate domains (GI) of rat
nucleostemin (aa 106-459) was subcloned in the pAS2-1 vector as a bait to screen
a 7-day-old mouse embryo cDNA library in pACT2 (Clontech). The bait
and library plasmids were co-transformed into Saccharomyces cerevisiae strain
Y190 and selected for both histidine+ and -galactosidase+ phenotypes. cDNA
plasmids were electroporated into Escherichia coli HB101 and amplified for
sequencing.
Coimmunoprecipitation
Cells were harvested in NTEN buffer (20 mM Tris pH 8.0, 150 mM NaCl, 1 mM
EDTA, 0.5% NP40, 0.1 mM DTT, supplemented with 1 mM PMSF, 1 g/ml
leupeptin, 0.5 g/ml aprotinin, 0.7 g/ml pepstatin A, and 1 M E64). Lysates were
incubated with monoclonal anti-HA (HA.11, Covance), monoclonal anti-Myc
(9E10, Covance) or polyclonal anti-nucleostemin (Ab1164) antibodies for 1 hour
at 4°C, followed by incubation with protein-G sepharose beads (Pharmacia) for
another 4 hours at 4°C. Immunoprecipitates were washed five times with RIPA
buffer (1 PBS, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP40, 1 mM PMSF,
1 g/ml leupeptin, 0.5 g/ml aprotinin, 0.7 g/ml pepstatin A, and 1 M E64),
fractionated by 10% SDS-PAGE, and transferred to Hybond-P membranes
(Amersham). Specific signals were detected by western blot analyses using
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polyclonal anti-HA or anti-Myc primary antibodies and horseradish peroxidase-
conjugated secondary antibodies.
GST pull-down assay
Full-length and partial cDNAs of RSL1D1 and nucleostemin were subcloned into
the pGEX4T-2 vector. GST fusion proteins were expressed in BL21/DE3 as
described previously (Tsai and McKay, 2002). Epitope-tagged proteins were
expressed in HEK293 cells and extracted in PBS–Triton-X-100 (1%) buffer,
supplemented with protease inhibitors. Sepharose-bound GST fusion proteins (2
g) were incubated with cell lysates for 2 hours at 4°C, washed five times with
extraction buffer, including twice with high-salt solutions (500 mM NaCl),
fractionated on 10% SDS-PAGE and detected by western blottings.
Northern blot analyses
Ten micrograms of total RNAs were isolated from CD-1 mice using Trizol solutions
(Invitrogen), fractionated on a 1% formamide denaturing agarose gel, and
transferred onto Hybond XL membrane (Amersham). Filters were then hybridized
with -32P-labeled probes at 65°C overnight and washed with high-stringency
buffer. Plaque date was counted as embryonic day 0.5 (E0.5).
siRNA knockdown
siRNA duplexes were designed to target the sense sequence 5-
AGTGGTTCTTGCAGTGCTA-3 in the human RSL1D1 gene and a scrambled
sequence 5-TGACGATCAGAATGCGACT-3 (Dharmacon). Cells were
transfected with siRNA duplexes (100 nM) for 15 hours using the Oligofectamine
reagent (Invitrogen), and fixed with 4% paraformaldehyde 3 days after transfection.
The distributions of endogenous nucleostemin and B23 were detected by anti-
nucleostemin (Ab2438) and anti-B23 immunofluorescence and counterstained with
DAPI.
FRAP analysis
CHO cells grown in Nalgene Lab Tek II chamber slides were transfected with 0.6
g plasmid DNA using Lipofectamine-Plus reagents 1 day before the measurement.
Bleaching experiments were performed on a Zeiss LSM510 confocal microscope
with a 63 plan-apochromat oil objective. The photobleaching protocol was
modified based on previous reports (Dundr et al., 2000; Phair and Misteli, 2000).
The GFP signal was excited with the 488 nm argon laser (20 mW nominal output),
and emission was monitored above 505 nm. Cells were maintained at 35°C with a
heat blower throughout the entire procedure. A spot of 1 m in diameter was
bleached within the nucleolus using a short laser pulse administered at 100% power
for three iterations. All experiments were ensured to achieve 70-80% bleaching of
the original intensity. For image acquisition, the laser power was attenuated to 0.6%
of the bleach intensity, and cells were scanned with 5 zoom at 0.29-second
intervals for 31.6 seconds after photobleaching. For quantification, fluorescence
intensities of the region of interest, the entire nucleus, and the outside of the nucleus
were measured. Signal recovery in the bleached area (FRAP) was normalized to the
total intensity in the nucleus after background subtraction and averaged over 20 cells
from three independent experiments. Cells with a signal loss of more than 10%
during the imaging phase were not used.
Image acquisition and analyses
Confocal images were captured on a Zeiss LSM510 confocal microscope using a
63 plan-apochromat oil objective. In Fig. 2, images were scanned with a 512512
frame size, 2 zoom, and <1.4 m optical thickness. For high-resolution studies
(Figs 4, 8, and supplementary material Fig. S2), images were scanned with a
512512 frame size and 4 zoom. Optical slices of 0.7 m were sampled by
setting the pinhole size at less than 1 Airy unit. Detector gain and amplifier offset
were adjusted to ensure all signals were appropriately displayed within the linear
range. Immunofluorescent images were captured on a Zeiss Axiovert 200
microscope using a 63 plan-apochromat oil objective and a CoolSNAPEZ
Monochrome camera (Photometrics, 6.456.45-m pixels). Exposure time was set
so that the brightest intensity reached 80% of the saturation intensity. For the siRNA
experiments, captured images were analyzed using the ImageJ 1.36b software
(http://rsb.info.nih.gov/ij/). The nucleolar size, the ratio of nucleolar-to-nuclear area,
and the ratio of nucleolar-to-nucleoplasmic (N/P) fluorescence intensity were
measured from 130 cells randomly sampled from seven independent experiments
in a double-blind study. All nucleolar regions within a single cell were delineated.
The average intensities of the whole nucleolar and nucleoplasmic areas were
calculated to generate the N/P intensity ratio. Areas were measured in pixels (100
pixels equal 0.89 m2).
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